ReNerve Secures First Middle East Approval for NervAlign Nerve Cuff in Bahrain

ReNerve Limited (ASX: RNV) has achieved a significant milestone by securing marketing approval for its flagship NervAlign® Nerve Cuff™ in Bahrain. This marks the Company’s first regulatory success in the Middle East, facilitated through its regional partner, Union MediScience B.S.C.

The two companies will now collaborate on the commercial rollout of NervAlign® in Bahrain, using clinical data from early adopters to support expansion into broader Middle East and North Africa (MENA) markets. With the MENA nerve repair market valued at over USD$80 million annually and growing at 35%, this approval represents a strategic entry point with substantial commercial upside. ReNerve aims to capitalize on this momentum through regional growth and innovation.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com